5 Best Momentum Stocks to Buy According to Analysts

2. ImmunityBio Inc. (NASDAQ:IBRX)

Analyst Upside: 66.20%

ImmunityBio Inc. (NASDAQ:IBRX) is one of the best momentum stocks to buy according to analysts. ImmunityBio Inc. (NASDAQ:IBRX) announced on May 19 that the U.S. Food and Drug Administration accepted for review the supplemental Biologics License Application for ANKTIVA® in combination with Bacillus Calmette-Guerin to treat patients with BCG-unresponsive non-muscle invasive bladder cancer with papillary disease without carcinoma in situ. Management stated that the FDA assigned a PDUFA target action date of January 6, 2027, and that the supplemental BLA seeks to expand the ANKTIVA label to include patients with BCG-unresponsive NMIBC with papillary disease.

In a separate development, ImmunityBio Inc. (NASDAQ:IBRX) received a rating update from BTIG following the release of financial results for fiscal Q1. The firm cut the price target on the stock to $12 from $13, maintaining a Buy rating on the shares. It also reaffirmed the $44.2M in ANKTIVA sales pre-announced last month, which was up 15% q/q and 168% y/y.

ImmunityBio, Inc. (NASDAQ:IBRX) is a clinical-stage immunotherapy company that develops next-generation therapies to treat cancer and infectious diseases. Its immunotherapy platform activates the adaptive and innate immune systems to create long-term immunological memory.

1281292 - 11759070 - 1